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Abstract
Background: Bone generation and maintenance involve osteoblasts, osteoclasts, and osteocytes which originate from
unique precursors and rely on key growth factors for differentiation. However, an incomplete understanding of bone
forming cells during wound healing has led to an unfilled clinical need such as nonunion of bone fractures. Since circulating
monocytes are often recruited to sites of injury and may differentiate into various cell types including osteoclasts, we
investigated the possibility that circulating monocytes in the context of tissue injury may also contribute to bone repair. In
particular, we hypothesized that LL-37 (produced from hCAP-18, cathelicidin), which recruits circulating monocytes during
injury, may play a role in bone repair.
Methods and Findings: Treatment of monocytes from blood with LL-37 for 6 days resulted in their differentiation to large
adherent cells. Growth of LL-37-differentiated monocytes on osteologic discs reveals bone-like nodule formation by
scanning electron microscopy (SEM). In vivo transplantation studies in NOD/SCID mice show that LL-37-differentiated
monocytes form bone-like structures similar to endochondral bone formation. Importantly, LL-37-differentiated monocytes
are distinct from conventional monocyte-derived osteoclasts, macrophages, and dendritic cells and do not express markers
of the mesenchymal stem cells (MSC) lineage, distinguishing them from the conventional precursors of osteoblasts.
Furthermore, LL-37 differentiated monocytes express intracellular proteins of both the osteoblast and osteoclast lineage
including osteocalcin (OC), osteonectin (ON), bone sialoprotein II (BSP II), osteopontin (OP), RANK, RANKL, MMP-9, tartrate
resistant acid phosphatase (TRAP), and cathepsin K (CK).
Conclusion: Blood derived monocytes treated with LL-37 can be differentiated into a novel bone forming cell that functions
both in vitro and in vivo. We propose the name monoosteophil to indicate their monocyte derived lineage and their bone
forming phenotype. These cells may have wide ranging implications in the clinic including repair of broken bones and
treatment of osteoporosis.
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Introduction
Bone generation, maintenance and healing are complicated
processes in which osteoblasts, osteoclasts, and osteocytes are
known to play important roles. Osteoblasts, which are derived
from mesenchymal stem cells (MSCs) [1], express marker genes for
bone sialoprotein (BSP) and osteocalcin (OC). Osteoclasts, which
are derived from monocytes by the action of macrophage colony-
stimulating factor (M-CSF) and receptor activator of nuclear factor
kB ligand (RANKL), effect bone resorption by removing its
mineralized matrix and breaking up the organic bone [2]. In
addition to these two types of cells, the bone contains osteocytes
which are trapped in the bone matrix and cease to generate
osteoid and mineralized matrix. The function of osteocytes is
considered as inactive osteoblasts or bone lining cells [3] that
undergo programmed cell death [3,4]. However, the origin of
bone forming cells during wound healing is less well studied. An
unfilled clinical need of increasing bone mass such as nonunions of
bone fracture indicated that unknown types of cells are involved in
bone formation [5]. In the case of wound repair, monocytes play a
critical role in the formation of new blood vessels [6,7,8,9] and
often differentiate into tissue specific lineages as required by the
tissue of injury [10,11]. Given the known plasticity of monocytes in
wound repair, we speculated that monocytes may also contribute
to bone repair not only as monocyte-derived bone absorbing
osteoclasts, but also as yet to be defined bone forming cells. In
order to investigate this possibility, we examined the response of
monocytes to well known effectors of wound repair.
Among the many cytokines, chemokines, and other effectors
associated with wound repair, hCAP-18 stands out as candidate
with multiple effects on monocytes including the induction of
migration [12,13] and differentiation of monocytes to dendritic
cells (DCs) [14]. hCAP-18 is the only human member of the
cathelicidin family of antimicrobial peptides known to date [15].
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18, has been demonstrated to mediate a wide variety of immune
and inflammatory functions, including wound repair. In this
respect, growth factors involved in the process of wound healing
were shown to induce LL-37 expression [16]. In vitro, LL-37 was
shown to activate endothelial cells resulting in increased
proliferation and formation of vessel-like structures, while in vivo
cathelicidin (CRAMP)-deficient mice showed decreased vascular-
isation during wound repair [17]. LL-37 promotes re-epithelial-
ization of healing skin [18] and anti-LL-37 antibodies inhibit re-
epithelialization of skin wounds [19]. Furthermore, LL-37 induces
migration of human peripheral blood monocytes, neutrophils,
CD4
+ T cells, and mast cells [12,13,20,21] and influences the
expression of over 40 genes in murine RAW 264.7 macrophage
cells, in which some of these gene products are involved in bone
formation, including the bone morphogenetic protein (BMP) 1,
BMP-2, and BMP-8a [22]. Since LL-37 release increases during
inflammation including trauma and bone fracture and induces
several BMPs, we were interested in investigating the action of LL-
37 on monocytes and their potential role in new bone formation.
We show that LL-37 treated monocytes form large adherent
round cells after 6 days in culture, followed by the formation of large
adherent round and irregular cells after 63 days in culture. Growth
of LL-37-differentiated monocytes on osteologic discs for 7 weeks
reveal bone-like nodule formation by scanning electron microscopy
(SEM) and invivotransplantation studies inNOD/SCIDmiceshow
that LL-37-differentiated monocytes form bone-like structures
similar to endochondral bone formation. Moreover, LL-37-differ-
entiated monocytes are distinct from monocyte-derived macrophag-
es, dendritic cells (DCs), and osteoclasts according to their
morphology, surface markers, and/or cytokine profiles. In addition,
they do not express surface markers of the MSC lineage, clearly
distinguishing them from the conventional precursors of osteoblasts.
Interestingly, LL-37-differentiated monocytes express proteins of
boththe osteoblastand osteoclastlineage including osteocalcin(OC),
osteonectin (ON), bone sialoprotein II (BSP II), osteopontin (OP),
RANK, RANKL, MMP-9, tartrate resistant acid phosphatase
(TRAP), and cathepsin K (CK). Since our data indicates that LL-
37-differentiated monocytes are a new type of bone forming cell we
propose thenamemonoosteophil. The abilityto culturethese cells in
vitro may have wide ranging applications in the clinic including
augmenting repair of broken bones and treatment of osteoporosis.
Methods
Reagents
Recombinant human GM-CSF, M-CSF, IL-4, IFNa,a n d
RANKL were purchased from ProSpec Tany TechnoGene Ltd
(Rehovot 76124, Israel); LPS from E. coli (055:B5), Phalloidin, and
saponin from Sigma-Aldrich (St. Louis, MO, USA); anti-DC-SIGN
PerCP/Cy5.5 (CD209, clone 9E9A8), anti-CD1a PE/Cy5(Clone
HI149), anti-CD90 PerCP/Cy5.5 (Clone 5E10), anti-CD163-
PerCP/Cy5.5 (Clone GHI/61), anti-CD34 PerCP/Cy5.5 (Clone
4H11), and anti-MMP-9 (Clone F37P4A3) were purchased from
Biolegend Inc (San Diego, CA92121); anti-alkaline phosphatase
(ALP, clone B4-78), anti-osteocalcin PE (OC, Clone 190125), anti-
osteonectin (ON, Clone 122511), anti- RANKL (TRANCE, Clone
70525), anti-RANK (Clone 80707 were purchased from R& D
System (Minneapolis, MN 55413, USA); anti-bone sialoprotein II
(BSPII, Clone ID1.2), anti-osteopontin (OP, clone AKm2A1),
rabbit anti-human tartrate resistant acid phosphatase (TRAP) and
anti-human cathepsin K (CK) polyclonal antibodies were from
Santa Cruz Biotechnology Inc (Santa Cruz, CA. 95060); anti-CD1b
FITC(CloneM-T101),anti-CD16-PerCP-Cy5.5(Clone3G8),anti-
CD14-FITC (clone M5E2), isotype controls, and BioCoat
TM
Osteologic
TM Disc were from BD Biosciences (Chicago, IL,
USA); anti-CD1c FITC (Clone AD5-8E7) was from Miltenyi
Biotec Inc ( Auburn, CA95602); anti-CD45 PE (clone HI30) was
from eBiosciences (Dallas, TX75312); Alexa Fluor 488 goat anti-
mouse IgG (H+L), Alexa Fluor 488 goat anti-rabbit IgG (H+L), and
Alexa Fluor 488 chicken anti-goat IgG (H+L) were from Invitrogen
Corp (Chicago, IL60690); Hard Set mounting medium with DAPI
was from Vector Laboratories (Burlingame, CA, USA); EasySepH
Human Monocyte Enrichment Kit was from StemCell Technolo-
gies Inc (Vencouver, Canada); FBS and human serum were from
Irvine Scientific (Santa Ana, CA, USA); LL-37 was synthesized,
prepared and stored as previous reports[13,23]. Briefly, LL-37 was
synthesized by the standard FMOC chemistry, purified by reversed
phase HPLC, and the mass verified by nanospray mass spectrom-
etry. The concentration was determined by amino acid analysis.
Monocyte preparation and differentiation
The use of anonymous discard blood samples without the
requirement for informed consents was approved by the City of
Hope IRB, IRB number 99132. Peripheral blood mononuclear
cells (PBMCs) were isolated from citrated human blood (discard
blood from anonymous donors) by centrifugation over Ficoll-
Paque Plus (GE healthcare biosciences, Pittsburgh, PA, USA)
density gradient. Monocytes were separated using EasySepH
Human Monocyte Enrichment Kit (StemCell Technologies Inc,
Vencouver, Canada) from PBMCs. The purified monocytes were
stained with anti-CD14-FITC and checked by using flow
cytometry FACSCanton II. Monocytes with .95% purity were
suspended at 1610
6 cells/mL in RPMI 1640 medium supplement
with 10% FBS (FBS contained ,5 pg/100 mL LPS).
After isolation, monocytes were treated with serial dose of LL-
37 (0.625 mM, 1.25 mM, 2.5 mM, 5 mM, or 10 mM) for differen-
tiation for 3 days, 6 days, 14 days or more. After incubated for 6
days, cultures were fed every 2 days by removing half of the
supernatant and adding fresh medium. For macrophage differen-
tiation, monocytes were treated with medium only [24], with
100 ng/mL LPS [25], 10 ng/mL GM-CSF (macrophage 1, Mw1),
or 50 ng/mL M-CSF (macrophage 2, Mw 2) for 6 days [26].
Monocyte-derived DCs were generated with 1,000 U/mL GM-
CSF and 500 units/mL IL-4 [26] or GM-CSF and 1000 U/mL
IFNa [27]. Osteoclast were differentiated from monocytes in the
presence of RANKL and M-CSF (both at 25 ng/mL) [28].
Cell lines
Clonogenic human MSCs were generously provided by Dr.
Carlotta A. Glackin (Department of Neurosciences, City of Hope)
and incubated in a-MEM supplemented with 20% fetal calf serum
(FCS), 2 mM L-glutamine, and 100 mM L-ascorbate-2-phosphate
as previously described [29].
Microscopic observation of differentiated monocytes
Monocytes were plated in culture media and treated with LL-37
(dose shown in the figure), LPS (100 ng/mL), GM-CSF (10 ng/
mL), M-CSF (50 ng/mL), GM-CSF (1,000 U/mL ) /IL-4 (500
units/mL), GM-CSF (1,000 U/mL ) /IFNa (1,000 U/mL ), or M-
CSF/RANKL (both at 25 ng/mL) and photographed with the
Leica DMI 3000B (Leica Microsystems Inc, Bonnockburn,
IL60015) inverted microscope.
Phagocytosis
6-day LL-37-, medium-, LPS-, GM-CSF-, and M-CSF-
differentiated monocytes (1 610
6/mL) in tissue culture medium
LL-37 Treated Monocytes
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fluorescent labeled latex beads at a multiplicity ratio of 1:500, and
incubated for 1 h at 37uC. After washed three times, cells were
analyzed using FACSCanton II and Flowjo software.
Flow cytometry
For cell surface staining, cells were washed with PBS, blocked
with 10% human serum in PBS, stained with isotype controls and
antibodies described in the figures, washed 3 times with 1% BSA
PBS, and analyzed with a FACSCanton II. For intracellular
staining, cells were washed with PBS, fixed with 1% paraformal-
dehyde in PBS, permeabilized in PBS buffer containing 0.1%
saponin (Sigma-Aldrich) and 2% BSA, and stained with primary
isotype controls and antibodies shown in the figures. After washing
with PBS containing 1% BSA and 0.1% saponin, cells were
stained with secondary Alexa 488 conjugated antibodies. Stained
cells were assessed with a FACSCanton II cytometer, and
analyzed using Flowjo software.
Cytokine multiplex analysis
Fresh monocytes were plated at 1610
6 cells/mL in RPMI 1640
medium containing 10% FBS in 48-well plates and incubated with
medium only, LL-37, LPS, GM-CSF, M-CSF, M-CSF/RANKL
for 6 days, or/and 14 days and 21 days. Supernatant was collected
and analyzed using the Human Cytokine 30-Plex antibody bead
kit from Biosource International Inc, including IL-1b, IL-1ra, IL-
2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15,
IL-17, TNFa, IFNa, IFNc, G-CSF, GM-CSF, MIP-1a, MIP-1b,
MIG, RANTES, eotaxin, MCP-1, IP-10, VEGF, HGF, FGF-
basic, and HGF.
Cytokine concentrations were calculated using Bio-Plex Man-
ager 3.0 software with an eight-parameter, curve-fitting algorithm
applied for standard curve calculations [30].
Bone resorption assay
The resorbing activity was evaluated by using BioCoat
TM
Osteologic
TM Discs purchased from BD Biosciences as a mineral
matter in 24-well plate. Monocytes were incubated with M-CSF/
RANKL (both at 25 ng/mL) or 5 mM LL-37 on BioCoat
TM
Osteologic
TM Discs for 21 days in 5% CO2 atmosphere, then cells
were removed by exposure to NaOCl. The plates were washed by
rinsing distilled water and pit formation was observed by light
microscopy [31] and scanning electron microscopy (SEM). LL-37-
differentiated monocytes and M-CSF/RANKL-differentiated
osteoclasts were also incubated on BioCoat
TM Osteologic
TM Discs
for 7 weeks and fixed with 2.5% glutaraldehyde in 0.1 M
phosphate buffer for SEM.
Scanning electron microscopy (SEM)
BioCoat
TM Osteologic
TM Discs fixed in 2.5% glutaraldehyde in
0.1 M phosphate buffer, pH 7.2 (buffer A) for 1 h from bone
resorption assay were washed three times in buffer A, postfixed
with 1% osmium tetroxide in buffer A, then dehydrated in graded
ethanol. The 100% ethanol solution was then replaced by
propylene oxide, and the cells were embedded in Eponate. Thin
sections were stained with uranyl acetate and lead citrate and
examined with a FEI TECNAI G2 electron microscope.
In Vivo transplantation studies and histological
examination
All animal research was conducted according to IACUC
guidelines. This research was approved by the City of Hope
IACUC animal welfare committee protocol number 09028.
Approximately 5.0610
6 monocytes plus LL-37 (5 mM) were
mixed with 40 mg of hydroxyapatite/tricalcium phosphate (HA/
TCP) ceramic powder (Zimmer Inc, Warsaw, IN) and then
transplanted subcutaneously into the dorsal surface of 10-week-old
immunocompromised NOD/SCID mice for 7 weeks [29].
5.0610
6 monocytes alone, LL-37 (5 mM) alone or blank control
were mixed with 40 mg of hydroxyapatite/tricalcium phosphate
(HA/TCP) ceramic powder as controls. Harvested implants were
fixed in 10% formalin neutral buffered solution, decalcified in 10%
EDTA, and embedded in paraffin. Four-micrometer-thick sections
were stained with hematoxylin and eosin, and trichrome. For
immunohistochemistry, sections were stained usingprimary mouse
anti-human BSP II monoclonal (Santa Cruz Biotechnology Inc)
and secondary biotinylated rabbit anti-mouse IgG.
Statistical analysis
Assay results are expressed as means6SE and unpaired
Student’s t-tests were used for comparisons. All p-values are two-
sided. Data were analyzed with SPSS software (release 10.0, SPSS,
Chicago, IL, USA) and GraphPad Prism software (version 5.0,
GraphPad Software, San Diego, CA, USA).
Results
LL-37 induces monocyte differentiation and survival
After treatment with LL-37 for 6 days, monocytes differentiated
into large round adherent cells in comparison with untreated cells
that remained as either small round suspended cells or underwent
cell death (Figure 1A). The numbers of 5 mM LL-37-treated cells
are significantly higher than untreated controls in agreement with
loss of cells in untreated controls by cell death (Figure 1B). The
maximum effect occurred at the dose of 5 mM LL-37 after which
higher doses ($10 mM) led to decreased cell numbers due to the
well known toxicity of LL-37 .10 mM [23,32]. After 14 days, the
cell number of untreated controls decreased further, but the LL-
37-differentiated monocytes survived with an apparent further
increase in the diameter of the round adherent cells. DAPI staining
showed that LL-37-differentiated round adherent cells have a
single nucleus in spite of their larger cell size (Figure 1C).
However after continuous culture for 63 days some of the large
round LL-37-differentiated monocytes became giant cells with a
multinucleated characteristic similar to osteoclasts (Figure 1D). In
addition to the large round cells, we noted the appearance of
irregular shaped cells at 63 days for cells treated with 1.25–
10.0 mM LL-37 (Figure 1D). Together these analyses indicate
that LL-37 can progressively differentiate monocytes into large
round adherent cells at early times with giant cells and irregular
shaped cells appearing at later times.
LL-37-differentiated monocyte has the ability of bone
formation in vitro
Culture of unfractionated peripheral-blood monocytes with M-
CSF and RANKL is sufficient to induce their differentiation in
vitro to osteoclasts [33]. The multinucleation characteristic of the
osteoclast is the most striking morphological feature distinguishing
the osteoclast from its monocyte precursor. Since LL-37-
differentiated monocytes at late times have the morphology of
giant cells of osteoclasts, it was likely that they would share their
function, namely the dissolution/absorption of bone. BioCoat
TM
Osteologic
TM Discs were used to evaluate the bone absorption
ability of LL-37-differentiated monocytes compared to in vitro
derived osteoclasts. After incubation on BioCoat
TM Osteologic
TM
Discs for 3 weeks following removal of cells by bleach, M-CSF/
RANKL-differentiated osteoclasts formed absorption pits on the
LL-37 Treated Monocytes
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TM Osteologic
TM Discs (Figure 2A) comparable to
published results [31]. Unexpectedly, LL-37-differentiated mono-
cytes formed refractile specks on the discs instead of classical
absorption pits when viewed by phase contrast microscope
(Figure 2B). Scanning electron microscopy (SEM) analysis
revealed that the refractile specks are composed of raised granules
on the surface of the BioCoat
TM Osteologic
TM discs (Figure 2C).
Higher magnification analysis demonstrated single and compound
granules on the discs with a shallow absorbed zone among
compound granules (Figure 2D). These results prompted us to
extend the incubation time from 3 weeks to 7 weeks and to include
cells on the discs for SEM analysis (i.e, no removal of cells by
bleach). As a control, M-CSF/RANKL-differentiated monocytes
on the osteologic discs are shown with one osteoclast and two
absorption zones (Figure 2E). In contrast, LL-37-differentiated
monocytes exhibit raised granules on the discs with inclusion of
granular material within the cells (Figure 2F–H). The identifi-
cation of the granules as mineralized material was verified by
positive von Kossa staining (Figure S1, Supplementary
Methods S1). These results demonstrate that LL-37-differentiat-
ed monocytes are bone-forming cells, distinct from in vitro derived
bone absorbing osteoclasts.
LL-37-differentiated monocytes were directly compared to
monocyte-derived osteoclasts for morphology, survival, surface
markers, and cytokine release. Our results showed that although
LL-37-differentiated cells are morphological similar, they survive
better than M-CSF/RANKL-derived osteoclasts after 28 days in
terms of cell numbers (Figure 2I). While both treatments showed
two adherent cell types, namely round large cells and irregular
shaped cells at 28 days, there was a higher percentage of irregular
shaped cells in osteoclast differentiation medium compared to LL-
37 differentiation medium at 6 days. Surface marker staining
showed that 6-day M-CSF/RANKL-treated monocytes expressed
higher levels of CD14, CD163, CD16 and CD90 compared to 6-
day LL-37-differentiated monocytes (Figure 2J). In addition,
cytokine release analysis showed that LL-37-differentiated mono-
cytes released lower levels of IL-1b, IL-6, MCP-1, but higher levels
of IL-1ra than osteoclasts after differentiation for all time points
analysed (Figure 2K). Furthermore, 6-day LL-37-differentiated
monocytes showed increased production of IL-1ra, IL-10, IL-12,
IP-10, and GM-CSF than 6-day M-CSF/RANKL-differentiated
monocytes in response to LPS (Figure 2K and Figure S2). The
cytokine release profile in response to LPS suggests that LL-37-
differentiated monocytes have an anti-inflammatory function.
Thus, these data demonstrate that although LL37-differentiated
cells share the morphology of giant cells similar to monocyte-
derived osteoclasts, they have distinctive cell surface markers and
cytokine release profiles.
Since LL-37-differentiated monocytes are not true osteoclasts,
then perhaps they share properties with mesenchymal stem cells
(MSCs) the precursors of osteoblasts? In the process of bone
generation and repair, MSCs differentiate into osteoblasts and
osteocytes. To answer this question, cell surface markers of both
LL-37-differentiated monocytes and MSCs were compared. As
expected, both MSCs and LL-37-differentiated cells don’t express
the bone marrow stem cell marker CD34. However, while MSCs
express CD90 (Thy1), a marker for a variety of stem cells, they
don’t express CD45, a common leukocyte marker. In contrast, LL-
37-differentiated monocytes express CD45 and do not express
CD90 (Figure S3). Moreover, LL-37-differentiated monocytes
Figure 1. LL-37 induces monocyte differentiation. Negatively isolated monocytes at the concentration of 1610
6/mL were incubated in RPMI
1460 medium with 10% FBS in the presence or absence of LL-37. A. Cell morphology was shown by phase contrast microscopy (magnification 2006).
B. Monocytes were incubated in the presence or absence of 5 mM LL-37 for 6 days. Cells were harvested and counted by hemocytometer. Data (mean
6 SE) was from four independent experiments performed. ** p,0.01 vs control. C–D. Monocytes treated with 5 mM LL-37 for 14 days (C) or 63 days
(D) were fixed, permeablized, stained with DAPI, and observed by fluorescent microscopy. Multinucleated giant cell formation was found in 63-day
LL-37-treated monocytes. Images represent one of four independent experiments.
doi:10.1371/journal.pone.0013985.g001
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exhibit spindle shape morphology only (data not shown).
Furthermore, when cultured under osteogenic inductive condi-
tions on BioCoat
TM Osteologic
TM Discs, MSC exhibited a
different pattern of bone formation compared with LL-37-
differentiated monocytes as indicated by using SEM (Figure
S4). Thus, we conclude that LL-37-differentiated monocytes,
distinct from both osteoclasts and precursor of osteoblasts, are a
new type of bone forming cells. In additional to the three types of
bone cells, osteoclast from M-CSF/RANKL-derived monocyte,
osteoblast from MSC, and osteocyte from MSC-derived osteo-
blast, we can now add LL-37-differentiated monocytes as a fourth
type. We propose the name ‘‘monoosteophil’’ to distinguish them
from the three known types of bone cells and to emphasize their
bone loving behavior generated from monocytes.
Bone formation of monoosteophils in vivo
The capacity of the monoosteophils to form ectopic bone when
transplanted with hydroxyapatite/tricalcium phosphate (HA/
TCP) ceramic particles subcutaneously in NOD/SCID mice was
examined. Histologic analysis of hematoxylin and eosin (H&E)
sections representing 7 week old transplants showed that
monoosteophil implants did not stain red for bone matrix-like
structures as observed for MSC implants [29]. An epiphyseal-like
structure was observed only in the monoosteophil group but not in
three control groups (monocytes alone, LL-37 alone, and blank
control) (Figure 3A–D). Epiphyseal-like structures are usually
seen in the proliferating layer of growth plates in the histologic
stages of long bone and epiphyseal development [34,35]. Masson
trichrome staining showed that the epiphyseal-like structure
contains collagen (blue color) (Figure 3E–H). When the origin
of the cellular material in the recovered implants was assessed
using anti-human BSP II antibody, the interstitial tissue and cells
within the epiphyseal-like structure were found to stain positive for
anti-human BSP II, confirming their human origin (Figure 3I–L).
These results suggest that monoosteophils have the ability to form
bone-like structures similar to the proliferating layer of growth
plates.
The monoosteophil is distinct from in vitro differentiated
macrophages and dendritic cells
Circulating monocytes have the capacity to differentiate into a
variety of phagocytes, including macrophages, dendritic cells
(DCs), osteoclasts, microglia in the central nervous system, and
Kupffer cells in the liver [36,37,38,39]. Thus, it was important to
compare monoosteophils to monocyte-derived macrophage and
Figure 2. LL-37-differentiated monocytes are a novel type of bone forming cells (monoosteophils). Monocytes were incubated in the
presence of M-CSF/RANKL (both at 25 ng/mL, A, E)o r5mM LL-37 (B,C,D,F,G,H) on BioCoat
TM Osteologic
TM Discs in 5% CO2 atmosphere. After
incubation for 3 weeks, cells were removed with bleach and observed by phase contrast microscopy (magnification6200, A, B) or scanning electron
microscopy (SEM) (C, D). Pit formation was shown on the disc incubated with M-CSF/RANKL-differentiated monocytes (A). Refractile specks were
shown on the disc incubated with LL-37-differentiated monocytes (B). SEM showed the refractile specks are built-up granules with a shallow
absorbed zone (C, D). After incubation for 7 weeks, pit formation and osteoclast are shown on the disc incubated with M-CSF/RANKL-differentiated
monocytes by using SEM (E), and built-up structures and cells are shown on the disc of LL-37-differentiated monocytes (F–H). Monocytes at
concentration of 1610
6/mL were incubated with 5 mM LL-37 or M-CSF/RANKL (both at 25 ng/mL). I. Morphology was evaluated by phase contrast
microscopy (magnification 2006). J. After incubation for 6 days, LL-37- and M-CSF/RANKL-differentiated monocytes were harvested, stained with
antibodies, and analyzed by flow cytometry. K. Cytokine levels in the supernatant of LL-37- and M-CSF/RANKL-differentiated monocytes were
analyzed. In the LPS treated experiment, 6-day LL-37- and M-CSF/RANKL-differentiated monocytes were collected, resuspended at the concentration
of 1610
6/mL, and incubated with 100 ng/mL LPS for 18 h and cytokine levels were detected in the supernatant (mean 6 SE, n=3). Data represent
three independent experiments performed. M+R: M-CSF+RANKL. ** p,0.01, *** p,0.001 in comparison with M-CSF/RANKL-differentiated
monocytes; ## p,0.01 in comparison with M-CSF/RANKL-differentiated monocytes treated with LPS for 18 h.
doi:10.1371/journal.pone.0013985.g002
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macrophages from monocytes, including incubation with medium
only [24], LPS [25], GM-CSF to produce Mw1, or M-CSF to
produce Mw2 [26]. As shown in Figure 4A, the morphology of
LL-37-differentiated cells at 6 days is distinct from monocytes
treated with medium, LPS, GM-CSF or M-CSF. Interestingly, a
phagocytosis assay showed that the LL-37-differentiated cells
retain their phagocytic function similar to the other generated
Figure 3. Bone formation of monoosteophils in vivo. NOD/SCID mice were implanted subcutaneously with hydroxyapatite/tricalcium phosphate
only (A,E, I), or with 5 mM LL-37 (B, F, J), or with 5610
6 monocytes (C,G,K), or 5 mM LL-37 plus 5610
6 monocytes (D,H,L). Implants were harvested 7
weeks later and sections stained with haematoxylin and eosin (A–D), masson trichrome (E–H), and anti-human BSP II antibody (I–L) (1006).
doi:10.1371/journal.pone.0013985.g003
Figure 4. Comparison of monoosteophils with monocyte-derived macrophages. Negatively isolated monocytes at the concentration of
1610
6/mL were incubated in the presence or absence of 100 ng/mL LPS, 5 mM LL-37, 10 ng/mL GM-CSF, or 50 ng/mL M-CSF for 6 days. A. Cell
morphology was shown by phase contrast microscopy (magnification 2006). B. 6-day medium-, LPS-, LL-37-, GM-CSF-, or M-CSF-differentiated
monocytes at the concentration of 1610
6/mL were mixed with fluorescent labeled latex beads at a multiplicity ratio of 1:500, incubated at 37uC for
1 h, and analyzed by flow cytometry to show phagocytosis (MFI, mean fluorescence intensity). C. After monocytes were incubated with medium, LPS,
LL-37, GM-CSF, and M-CSF for 6 days, cytokine/chemokine levels in cultured supernatant were analyzed (pg/mL, mean 6 SE). D. 6-day medium-, LPS-,
LL-37-, GM-CSF-, or M-CSF-differentiated monocytes were harvested, stained with antibodies, and analyzed by flow cytometry. Data shown were from
three or four independent experiments.
doi:10.1371/journal.pone.0013985.g004
LL-37 Treated Monocytes
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although this assay may not faithfully predict phagocytosis of
opsonized bacteria. Cytokine profiles from the supernatants of 6-
day LL-37 treated monocytes showed that LL-37-differentiated
monocytes produce significantly less IL-1b and IL-6 and increased
IP-10 in comparison with macrophages generated by the other
methods (Figure 4C and Supplementary Table S1). Impor-
tantly, LL-37-differentiated monocytes release the highest levels of
IL-1ra, the natural antagonist of IL-1b, and the lowest level of IL-
1b compared to the other macrophage lineages. This suggests that
LL-37-defferentiated monocytes do not function as inflammatory
cells, at least according to inflammatory cytokine release, a result
similar to our previous report that LL-37 induces IL-1ra release
from neutrophils [23]. Moreover, cell surface marker staining
showed that LL-37-differentiated monocytes expressed lower levels
of CD163, DC-SIGN, and CD14 (Figure 4D) in comparison
with the other macrophages lineages. Thus, although LL-37-
differentiated monocytes retain their phagocytic ability, they are
distinct from other in vitro generated macrophages in terms of cell
morphology, cytokine release, and cell surface markers.
Besides the differentiation of monocytes along the macrophage
pathway, monocytes can also differentiate into DCs when cultured
in the presence of GM-CSF and IL-4 [40,41] or GM-CSF and
IFNa [27]. DCs are key players of adaptive immunity, unique in
their ability to activate naı ¨ve T lymphocytes by operating as
professional antigen-presenting cells (APC) to trigger a primary
immune response. DCs are classified as immature prior to
stimulation with agents such as LPS and as mature DCs after
treatment with LPS, at which point they exhibit dendritic
morphology [42,43]. To investigate their interrelationships, LL-
37-differentiated monocytes were compared to in vitro prepared
DCs. As shown in Figure 5A, LL-37-differentiated monocytes
express lower levels of CD1a and DC-SIGN than untreated
controls and do not express CD1b and CD1c, typical markers of
DCs [40]. The morphology of LL-37-differentiated monocytes is
distinct from GM-CSF/IL-4- and GM-CSF/IFNa-derived imma-
ture DCs in culture for 3 or 6 days. After incubation with LPS for
3 days, GM-CSF/IL-4- and GM-CSF/IFNa-derived immature
DCs showed mature dendritic morphology, a morphology not
observed for LL-37-differentiated cells or untreated cells
(Figure 5B). These results demonstrate that monoosteophils do
not share the characteristics of monocyte-derived DCs regarding
cell surface markers and cell morphology.
Other characteristics of monoosteophils
Given that monoosteophils are a novel type of bone forming cells,
weperformed additionalstudiestofullycharacterizetheirproperties.
Since monoosteophils have the abilityof using existing bonematerial
Figure 5. Monoosteophils are distinct from dendritic cells. Negatively isolated monocytes at the concentration of 1610
6/mL were incubated
in the presence or absence of 5 mM LL-37, 1,000 U/mL GM-CSF/500 U/mL IL-4, GM-CSF/IFNa (both at 1,000 U/mL). A. After incubation for 6 day,
LL-37-differentiated monocytes were harvested, stained with antibodies, and analyzed by flow cytometry. B. Morphology of medium-, LL-37-, GM-
CSF/IL-4-, and GM-CSF/IFNa-differentiated monocytes in the presence or absence of LPS were shown by phase contrast microscopy (magnification
2006). Images shown were from one of four independent experiments.
doi:10.1371/journal.pone.0013985.g005
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both osteoclast and osteoblast lineages. Indeed, phalloidin staining
showed that after differentiation for 6 days most monoosteophils are
round adherent cells with actin rings (Figure 6A), similar to
osteoclasts but mononuclear. In addition, 6 day monoosteophils
express a low level of TRAP, a marker normally expressed by bone-
resorbing osteoclasts and activated macrophages, on their cell
surface [44]. However, 6 day monoosteophils don’t express other
surface markers of osteoclasts including RANK, MMP-9, and
cathepsin K (Figure 6B). In comparison to osteoblast markers, they
do not express surface alkaline phosphatase (ALP), OC, osteonectin
(ON), BSP II, or osteopontin (OP) (Figure 6B). Interestingly,
intracellular staining results showed that 6-day monoosteophils do
express most of the expected osteoblast and osteoclast proteins
except ALP (Figure 6C), which is one of the most prominent
markers of MSC-derived osteoblasts. Intracellular staining also
reveals the presence of RANKL in LL-37 treated monocytes,
suggesting that RANKLmay belocallyreleased bythesecells.These
data indicated that monoosteophils share the actin ring of the
osteoclast, and express some marker proteins of the osteoclast and
osteoblast but these marker proteins are localized to the cytoplasm
and not to the cell surface.
Figure6.Characteristics ofmonoosteophils. Monocytes wereincubated in thepresenceof5 mM LL-37 for6 days. A. cells werefixed,permeabilized,
stained with phalloidin-Alexa 594 and DAPI, and observed by using fluorenscence microscope. B. cells were harvested, stained with antibodies, and
analyzed by using flow cytometry to show surface staining of proteins. C. Cells were harvested, fixed and permeabilized, stained with antibodies, and
analyzed by using flow cytometry to show intracellular staining of proteins. Data shown were from one of four independent experiments.
doi:10.1371/journal.pone.0013985.g006
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Bone is a dynamic tissue that undergoes constant remodeling in
which old bone is degraded by osteoclasts, the bone-resorbing cell,
and subsequently replaced by new bone formed by osteoblasts, the
bone-forming cell [33,45,46]. It is known that osteoblasts are
derived from mesenchymal stem cells (MSCs) through a multi-step
differentiation pathway [46]. Here, our data suggested that LL-37-
differentiated monocytes (monoosteophils), which have different
cell surface markers compared to MSCs, are a new type of bone
forming cell. Moreover, monoosteophils express some character-
istic proteins of both osteoblasts and osteoclasts.
Interestingly, both monoosteophils and osteoclasts are differen-
tiated from monocytes. When monocytes are treated with M-
CSF/RANKL, they differentiate into osteoclasts that exhibit a
bone resorbing phenotype, but when monocytes are treated with
LL-37, they produce monoosteophils with a bone formation
phenotype. Thus, the environmental niche of monocytes may
determine their ultimate phenotype. In the bone marrow where
monocytes are exposed to M-CSF and RANKL, they become
osteoclasts, but in an external wound-healing environment
exposed to LL-37, they become monoosteophils. Circulating
monocytes play an important role in development and homeosta-
sis, in part via the removal of apoptotic cells and scavenging of
toxic compounds [47]. Circulating monocytes also are accessory
cells, linking inflammation and the innate defense against
microorganisms to adaptive immune responses. In fact, circulating
monocytes are a considerable systemic reservoir of myeloid
precursors for the renewal of some tissue macrophages, antigen-
presenting DCs [48,49,50]. Recently, it was reported that
circulating monocytes have the potential to differentiate to a
variety of cell types such as multipotential cells and endothelial
cells other than phagocytes [10,11]. For example, monocyte-
derived multipotential cells (MOMC), having a unique phenotype
positive for CD14, CD45, CD34, and type I collagen with a
fibroblast-like morphology, can be obtained in cultures of
peripheral blood mononuclear cells (PBMC) for 7 to 10 days on
fibronectin-coated plastic plates supplemented with 10% fetal
bovine serum as the only source of growth factors [10]. However,
it should be noted that MOMC were isolated from PBMCs rather
than from purified monocytes. Moreover, MOMC are spindle
shape cells and monoosteophils contain both large round and
irregular shaped cells. Furthermore, MOMC are CD14, CD45,
CD34 positive, while monoosteophils are CD45 positive but CD14
and CD34 negative. Thus, monoosteophils are distinct from
MOMC regarding generation, morphology, and surface markers.
LL-37 is a potent modifier of DC differentiation and maturation
[14,51,52]. For example, monocytes that were co-cultured for 7
days with LL-37 and IL-4/GM-CSF were differentiated into DCs
[14]; treatment of GM-CSF/IL-4-derived immature DCs with
LL-37 and LPS suppressed the maturation and activation of DCs
by TLR ligands [51]; GM-CSF/IL-4-derived immature DCs
treated with LL-37 undergo internalization and subsequent
localization of LL-37 in the cytoplasmic and nuclear compart-
ments, causing an increased expression of HLA-DR and CD86
[52]. In our study, monoosteophils did not share dendritic cell
markers and morphology with either GM-CSF/IL-4- or GM-
CSF/IFNa-derived DCs. In another study, monocytes which were
treated with either GM-CSF or M-CSF plus LL-37 differentiated
to macrophages with an inflammatory phenotype [53]. Impor-
tantly, the main difference between our study and the other studies
is that we used LL-37 as a sole factor for monocyte differentiation
instead of combining LL-37 with other treatments which may
have directed differentiation along another lineages.
Our results showed that LL-37 at the concentration of
$1.25 mM #10 mM can induce monocyte differentiation. Impor-
tantly, these levels of LL-37 occur naturally during inflammation
[54,55,56,57,58,59]. So far, there is no report regarding the LL-37
concentration in the bone marrow or in bone undergoing repair.
Since LL-37 is released during inflammation, our data suggest that
the action of LL-37 on circulating monocytes may play an
important role in bone fracture and repair, given that mono-
osteophils have the ability to use existing bone material to build
new bone. We believe that subsequent studies will demonstrate a
physiological and pathophysiological function for these cells.
However, even in the absence of such studies, the in vitro
production of these cells may have important implications for
clinical situations demanding the rapid production of new bone in
the case of unrepaired breaks or osteoporotic lesions.
In summary, our results indicate that LL-37-differentiated
monocytes are a new type of bone forming cell, for which we
propose the name monoosteophil. Because the processes of bone
generation, remodeling, and repair are often compromised, the
healing of fractures and treatment of diseases such as osteoporosis
may benefit from the in vitro production of these novel bone
forming cells from monocytes.
Supporting Information
Figure S1 von Kossa staining of osteologic disc co-cultured with
LL-37-differentiated monocytes. Monocytes were incubated in the
absence or presence 5 mM LL-37 on BioCoat
TM Osteologic
TM
Discs in 5% CO2 atmosphere. After incubation for 5 weeks,
BioCoat
TM Osteologic
TM Discs were analyzed using von Kossa
staining to demonstrate mineralization (dark color indicates
mineral nodules). Original magnification: 2006.
Found at: doi:10.1371/journal.pone.0013985.s001 (4.81 MB TIF)
Figure S2 Comparison of cytokine release between LL-37-
differentiated monocytes and M-CSF/RANKL-differentiated
osteoclasts. Monocytes were incubated in the presence of 5 mM
LL-37 or M-CSF/RANKL (both at 25 ng/mL). Cytokine levels in
the supernatant of LL-37- and M-CSF/RANKL-differentiated
monocytes were evaluated using the Human Cytokine 30-Plex
antibody bead kit. In the experiment with LPS treatment, 6-day
LL-37- or M-CSF/RANKL-differentiated monocytes were col-
lected, resuspended at the concentration of 1610
6/mL, and
incubated with 100 ng/mL LPS for 18 h. Cytokine levels were
detected in the supernatant. Data (mean 6 SE) were from three
independent experiments performed. ## p,0.01 in comparison
with M-CSF/RANKL (M+R)-differentiated monocytes treated
with LPS for 18 h.
Found at: doi:10.1371/journal.pone.0013985.s002 (8.28 MB TIF)
Figure S3 LL-37-differentiated monocytes show surface marker
differences from mesenchymal stem cells (MSCs). MSCs and 6-day
5 mM LL-37-differentiated monocytes (monoosteophils) were
harvested, stained with antibodies, and analyzed by using flow
cytometry and Flowjo software. Data represent one of three
independent experiments performed.
Found at: doi:10.1371/journal.pone.0013985.s003 (3.43 MB TIF)
Figure S4 Differentiation of MSCs on osteologic disc. MSCs
were incubated in the a-MEM supplemented with 10% FCS,
100 mM L-ascorbate-2-phosphate, 10
27 M dexamethasone on
BioCoat
TM Osteologic
TM Discs in 5% CO2 atmosphere. After
incubation for 4 weeks, built-up structures and cells were shown
using SEM (A). The region shown in the rectangle was magnified
to show further details (B).
Found at: doi:10.1371/journal.pone.0013985.s004 (1.89 MB TIF)
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Found at: doi:10.1371/journal.pone.0013985.s005 (0.02 MB
DOC)
Table S1 Comparison of cytokine release of LL-37-differentiat-
ed cells for 6 days with medium, LPS, GM-CSF, and M-CSF
differentiated macrophages (Mean6SEM).
Found at: doi:10.1371/journal.pone.0013985.s006 (0.05 MB
DOC)
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